Abstract
Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Current Molecular Medicine
Title:Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Volume: 14 Issue: 7
Author(s): P. Vanichakarn, J. Hwa and J. Stitham
Affiliation:
Keywords: Coronary artery disease, hyperlipidemia, hypertension, pharmacogenetics, pharmacogenomics.
Abstract: Recent changes to the clinical management guidelines for hypertension and hyperlipidemia have placed emphasis on prevention through the pharmacological control and reduction of cardiovascular risk factors. In conjunction with proper diet and lifestyle changes, such risk factor control necessitates the use of safe and effective pharmacotherapy. However, many patients fail to reach or maintain therapeutic goals due to inadequacy and/or variability in response to antihypertensive and lipid-lowering medications. Thus, given the contribution of both hypertension and hyperlipidemia in the development and progression of cardiovascular disease, a personalized approach to pharmacotherapy, as well as disease prevention, seems particularly prudent. With the advancement of cardiovascular pharmacogenetics, the aim is to identify genetic biomarkers of drug-response and disease-susceptibility in order to make informed and individualized decisions, improving patient care through proper drug selection and dosing.
Export Options
About this article
Cite this article as:
Vanichakarn P., Hwa J. and Stitham J., Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115517
DOI https://dx.doi.org/10.2174/1566524014666140811115517 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Positive Airway Pressure in Sleep Disordered Breathing
Current Respiratory Medicine Reviews Nonfasting Hyperlipidemia and Cardiovascular Disease
Current Drug Targets Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Current Drug Targets Plasma Ghrelin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters Editorial: Management of Diabetes in Unique Populations
Current Diabetes Reviews Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science Anatomical and Functional Relationships Between Sensory Nerves and Mast Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial(Angiotensin II Receptor Research)
Current Pharmaceutical Design Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Design, Synthesis and ex vivo Study of the Vasorelaxant Activity Induced by Isosteric Derivatives of Dihydropyridines (NH→O)
Letters in Drug Design & Discovery